OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 200,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $1.74 per share, for a total transaction of $348,000.00. Following the purchase, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was bought at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.81 on Tuesday. The company’s 50 day simple moving average is $1.63 and its 200 day simple moving average is $1.57. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -9.53 and a beta of 1.70. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP grew its stake in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Barclays PLC lifted its holdings in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares during the period. BNP Paribas Financial Markets lifted its holdings in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 217,450 shares during the period. Intech Investment Management LLC acquired a new position in shares of OPKO Health during the third quarter valued at about $190,000. Finally, FMR LLC raised its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OPK shares. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Wednesday, March 12th. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.